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Analysis of PARP inhibitor toxicity by
multidimensional ﬂuorescence microscopy reveals
mechanisms of sensitivity and resistance
Jone Michelena1, Aleksandra Lezaja1, Federico Teloni1, Thomas Schmid1, Ralph Imhof1 & Matthias Altmeyer 1
Exploiting the full potential of anti-cancer drugs necessitates a detailed understanding of their
cytotoxic effects. While standard omics approaches are limited to cell population averages,
emerging single cell techniques currently lack throughput and are not applicable for com-
pound screens. Here, we employed a versatile and sensitive high-content microscopy-based
approach to overcome these limitations and quantify multiple parameters of cytotoxicity at
the single cell level and in a cell cycle resolved manner. Applied to PARP inhibitors (PARPi)
this approach revealed an S-phase-speciﬁc DNA damage response after only 15 min, quan-
titatively differentiated responses to several clinically important PARPi, allowed for cell cycle
resolved analyses of PARP trapping, and predicted conditions of PARPi hypersensitivity and
resistance. The approach illuminates cellular mechanisms of drug synergism and, through a
targeted multivariate screen, could identify a functional interaction between PARPi olaparib
and NEDD8/SCF inhibition, which we show is dependent on PARP1 and linked to PARP1
trapping.
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Following two seminal publications in 2005 demonstratinggreatly increased sensitivity of BRCA1/2 mutant cancer cellsto poly(ADP-ribose) polymerase (PARP) inhibition1,2,
PARP inhibitors (PARPi) have been extensively tested for their
potential as single therapeutic agents based on the concept of
tumor-speciﬁc synthetic lethality3–5. In 2014, olaparib (Lynparza,
AstraZeneca) was approved by the European Medicines Agency
(EMA) and the US Food and Drug Administration (FDA) for
the treatment of BRCA1/2 mutant ovarian cancers6. Several
additional PARPi, including talazoparib, niraparib, rucaparib and
veliparib, are currently in late phase clinical trial development or
have recently been approved7,8. PARPi target PARP enzymes
(mainly PARP1 and PARP2), which are DNA damage sensors
that catalyze the formation of negatively charged poly(ADP-
ribose) (PAR) chains to regulate protein assemblies and tune
chromatin dynamics in response to genotoxic stress9–13. Notably,
PARPs are not only implicated in maintaining genome stability,
but also have functions in various other cellular contexts,
including chromatin remodeling, transcription, and mRNA pro-
cessing, and they play important roles in cellular differentiation,
embryonic development, inﬂammation, metabolism, cancer
development, and aging14–17. While the mechanisms of action of
PARPi are incompletely understood and likely involve multiple
molecular events, including impaired recruitment of repair pro-
teins to sites of DNA damage, deregulated replication fork
reversal and reduced fork stability, as well as PARP trapping and
the formation of toxic PARP-DNA complexes that may give rise
to replication-associated DNA damage18–25, it has become clear
that an exquisite vulnerability to PARPi exists in cells with
compromised homologous recombination (HR) capacity26. This
synthetic lethal relationship between PARPi and compromised
HR function can explain the sensitivity of BRCA1/2 mutant cells
to PARPi, and strategies are currently being explored to identify
predictive biomarkers for PARPi sensitivity26.
Besides the current lack of strong predictive biomarkers for
PARPi responses, recently emerging mechanisms of PARPi
resistance in advanced disease complicate their clinical use. These
include regained HR capacity through restoration of BRCA1/2
function or through compensatory loss of functional antagonists,
reduced drug uptake through up-regulation of the P-glycoprotein
drug efﬂux transporter, and loss of PARP1 expression27,28.
Despite the broad interest in PARPi and their clinical potential,
how inhibition of PARP enzymes translates into cell death and
how cells can overcome PARPi sensitivity is currently not well
understood. In light of the clinical and pre-clinical challenges to
understand PARPi functions and evaluate their cellular effects,
experimental systems to assess PARPi toxicity at multiple levels in
a sensitive and quantitative manner are needed. Such systems
would enable the assessment of cellular mechanisms of PARPi
sensitivity and resistance and further reveal how PARPi resistance
might be overcome, e.g., through combined drug treatments.
Current methods employed to evaluate PARPi toxicity mostly
rely on long-term cell proliferation and clonogenic survival
assays, manual assessment of PARPi-induced DNA damage
markers such as γH2AX or RAD51 in relatively small cohorts
of cells, or biochemical cell fractionation for the detection
of chromatin-bound PARP129–34. Despite all beneﬁts, these
approaches are typically either time consuming, have limited
sensitivity, are not well suited for screening purposes, or focus
on single parameters of the cellular response to PARPi. Moreover,
cell-to-cell variation in PARPi responses is often not accounted
for and cannot be assessed in measurements of cell population
averages. This extends to cell cycle phase-speciﬁc responses,
which are common to many cytotoxic agents, and which
are easily lost in cell population averages of asynchronously
growing cells. High-throughput single-cell assays can discern
sub-population-speciﬁc responses and thereby reveal the
dynamics of cellular responses to drug perturbations35–38. More
speciﬁcally, high-content microscopy can be used to stage cells
according to their position in the cell cycle and to correlate cell
cycle dynamics with cellular stress responses39–46. In light of the
limitations associated with current tools used to dissect PARPi
responses, we aimed to exploit the power of single-cell analyses
for detailed multidimensional characterization of the cell biology
underlying PARPi toxicity. Building on the high resolution and
throughput of current ﬂuorescence microscopes, we used a ﬂex-
ible experimental workﬂow that discerns cell cycle phase speciﬁc
responses to PARPi and quantiﬁes relevant parameters of PARPi
cytotoxicity in a sensitive and reliable manner. It faithfully detects
differences in PARP1 trapping potential and toxicity of a panel of
clinically relevant PARPi, and reveals mechanisms of PARPi
sensitivity and resistance in BRCA1/2- and FANCD2-deﬁcient
cells and upon down-regulation of PARP enzymes, respectively.
Moreover, it is highly versatile and can be used to discern cellular
responses to a broad range of chemotherapeutic drugs and to
illuminate synergistic effects between PARPi and other genotox-
ins, even upon short-term treatments. Based on these analyses, we
reveal how PARPi and inhibition of the DNA damage response
kinase ATR synergize by promoting replication-born lesions to be
transmitted to mitosis where they give rise to catastrophic
chromosomal damage. We also reveal an unexpected role of the
PARP antagonist PARG in mediating PARPi-toxicity. Finally, a
targeted high-content imaging screen led to the identiﬁcation of
an interaction between PARPi and inhibition of the NEDD8/SCF
machinery, which we show is mechanistically linked to PARP1
trapping and can be rescued by PARP1 down-regulation. Asses-
sing cellular responses to PARPi by multidimensional ﬂuores-
cence microscopy thus provides a sensitive, reliable, easy-to-use
and cost-efﬁcient means to assess PARPi toxicity in low and high
throughput and to reveal mechanisms of PARPi sensitivity and
resistance.
Results
Quantitative image-based cytometry to measure PARPi toxi-
city. To evaluate PARPi effects on proliferating cancer cell
populations at the single-cell level, we employed automated
ﬂuorescence microscopy in combination with software-assisted
image analysis. We treated asynchronously growing U-2 OS cells
with the PARPi olaparib (Lynparza) and, using optimized
immunoﬂuorescence staining conditions for quantitative image-
based cytometry (QIBC)43–46, we stained for γH2AX (Serine139-
phosphorylated histone H2AX) and DNA content as a cell cycle
marker. We then used automated multi-position microscopy to
acquire image information of several thousand cells per condi-
tion. This enabled us to monitor effects of PARPi at the single cell
level and in a cell cycle resolved manner, thus illuminating the
dynamics and the cell cycle phase speciﬁcity of the response to
PARPi. Image-based cell cycle staging revealed a PARPi-induced
increase in γH2AX speciﬁcally in a sub-population of cells with
intermediate DNA content, while cells with low (2C) and high
(4C) DNA content did not show any measurable increase in
PARPi-evoked DNA damage response signaling (PARPi-DDR)
(Fig. 1a). Combined PARPi-DDR measurements with 5-ethynyl-
2'-deoxyuridine (EdU) labeling of DNA replication conﬁrmed
that the PARPi-induced γH2AX formation was indeed conﬁned
to the S-phase population (Supplementary Figure 1a, b). Thus,
PARPi leads to S-phase-speciﬁc DNA damage signaling, which
can be readily detected by QIBC independent of cell synchroni-
zation or other chemical or physical perturbations. This result
was conﬁrmed in the non-cancerous epithelial cell line RPE1
(Supplementary Figure 1c). To compare the sensitivity of our
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experimental system to alternative approaches, we exposed cells
to olaparib or treated them with ionizing radiation (IR) and
extracted histones for analysis by western blot. While IR-induced
phosphorylation of H2AX could be clearly detected, this was
not the case for the PARPi-treated samples (Supplementary
Figure 1d). Thus, QIBC is superior in sensitivity, presumably in
part due to its ability to demerge sub-population speciﬁc
responses. Indeed, when we synchronized cells in G1 and
released them into S-phase prior to histone extraction we were
able to detect a moderate increase in γH2AX upon PARPi
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Fig. 1 Quantitative analysis of PARP inhibitor toxicity by multidimensional ﬂuorescence microscopy. a Asynchronously growing populations of adherent U-2
OS cells were treated with 10 μM olaparib for 4 h, ﬁxed and stained for DNA content (DAPI) and the genotoxic stress marker γH2AX. Scatter plots depict
mean γH2AX and total DAPI intensities per nucleus. Each dot represents a single cell. Representative images of the untreated and olaparib-treated cell
populations and individual cells are shown on the right. b U-2 OS cells were treated with the indicated PARPi (all 10 μM) for 4 h and stained for γH2AX and
DNA content as before. γH2AX levels are shown as a function of cell cycle progression. A representative picture of niraparib-treated cells is shown on the
right. c Cells were treated as indicated, pre-extracted on ice in 0.2% Triton X-100 for 2 min prior to ﬁxation, and stained for γH2AX and DNA content.
γH2AX was quantiﬁed as a function of cell cycle progression. On the right, bar charts depict γH2AX levels as cell population averages from the same time-
course either focused on the whole cell population (top right) or on cells in mid S-phase (bottom right). Note that focusing the analysis on speciﬁc sub-
populations only (e.g., excluding cells in G1 and G2) greatly enhances the dynamic range of the analysis. p-values were obtained by Mann–Whitney test.
Color codes as deﬁned in the ﬁgure panels. Scale bars, 100 μm (large image ﬁelds) and 10 μm (single cell images)
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(Supplementary Figure 1e, f). Also ﬂow cytometry revealed
olaparib-induced γH2AX signaling in S-phase cells (Supplemen-
tary Figure 1g). However, compared to microscopy-based mea-
surements the sensitivity of both western blot and ﬂow cytometry
was extenuated and the lack of high-resolution cell images
represents an additional limitation that precludes analyses of
PARPi-induced changes at the subcellular level (see below).
Having validated the approach, we assessed a larger panel of
clinically relevant PARPi. Besides olaparib, several potent PARPi
are currently being tested in the clinics, including the third
generation PARPi veliparib (ABT-888, Abbvie), rucaparib
(AGO14699, Clovis) and niraparib (MK4827, Tesaro)7,8. We
also included PJ-34, a second generation PARPi that has
been used for blocking PARP catalytic activity for more than
15 years47. All compounds resulted in clearly detectable S-phase
speciﬁc γH2AX signaling after just 4 h of exposure, with niraparib
having the strongest and PJ-34 the weakest effect (Fig. 1b). While
single immunoﬂuorescence images reveal the vast cellular
heterogeneity in the response to PARPi, the high-content
imaging-based cell cycle staging precisely attributes the differ-
ential response to speciﬁc cell cycle phases (Fig. 1b, exempliﬁed
for niraparib). Remarkably, the observed differences in DNA
damage signaling (niraparib >> rucaparib >> olaparib >>
veliparib >> PJ-34) closely matched previously reported IC90
values for these compounds7,22,30 and they were well aligned with
cell proliferation measurements performed by high-content time-
lapse imaging over 72 h in absence or presence of PARPi
(Supplementary Figure 1h). Thus, QIBC-based short-term
measurements of PARPi-DDR in S-phase cells may be used as
a rapid readout for sensitivity to different PARPi. To fully exploit
the predictive capability of the system we aimed to further
enhance its sensitivity. Detergent-based pre-extraction of cells
prior to ﬁxation indeed enhanced the PARPi-induced γH2AX
signal (Supplementary Figure 1i) and allowed us to detect S-phase
DNA damage signaling as early as 15 min after olaparib addition
(Fig. 1c). Signiﬁcance testing of these data suggests that a
comparison of 400 cells per condition was enough to discriminate
PARPi-treated from untreated cells with reasonable (p < 0.05 at
15 min, Mann–Whitney test) to high conﬁdence (p < 0.0001 at
2 h). Importantly, focusing the analysis on sub-populations, e.g.
on S-phase cells only, greatly enhanced the dynamic range of the
quantitation (Fig. 1c, compare upper right panel for whole cell
populations to lower right panel focused on mid S-phase cells).
Taken together, these results demonstrate that quantitative
analysis of PARPi-DDR by ﬂuorescence microscopy is exquisitely
sensitive and can predict varying degrees of toxicity of clinically
relevant PARPi in short-term experiments.
Given that cancer cells with defects in the homologous
recombination (HR) pathway are hypersensitive to PARPi5, we
next tested whether we could detect HR intermediates in PARPi-
treated cells. The RAD51 recombinase forms ﬁlaments on damaged
DNA to pair with homologous DNA sequences and initiate HR
repair. These HR intermediates can be detected microscopically as
nuclear RAD51 foci upon DNA breakage or PARPi exposure48,49.
We observed a time-dependent increase in RAD51 foci as early as
1 h after PARPi treatment, which was most prominent in mid S-
phase cells (Supplementary Figure 2a). RAD51 foci were found in
cells containing the highest amount of γH2AX (Supplementary
Figure 2b), and in these cells we detected a decrease in replication
speed, which was associated with a delay in S-phase progression
(Supplementary Figure 2c). As expected, RAD51 foci formation was
completely dependent on the HR factors BRCA1 and BRCA2
(Supplementary Figure 2d). We next tested whether the QIBC-
based PARPi-DDR approach could faithfully recapitulate known
clinically relevant mechanisms of PARPi sensitivity, speciﬁcally loss
of BRCA1/21,2 and Fanconi anemia (FA) genes50,51. Although the
initial γH2AX response to PARPi was comparable between BRCA1/
2-depleted and control cells, knockdown of BRCA1 or BRCA2
markedly increased γH2AX in S/G2 after 16 and 48 h of PARPi
treatment (Fig. 2a, b). Image-based cell cycle staging of asynchro-
nous cells further revealed that loss of BRCA1/2 led to higher
amounts of mitotic DNA damage as demonstrated by γH2AX-
positive condensed mitotic chromosomes (Supplementary
Figure 3a), in line with recent work52. Similar to BRCA1/2
deﬁciency, loss of FANCD2 resulted in higher amounts of DNA
damage (Fig. 2c and Supplementary Figure 2e for knockdown
controls for BRCA1, BRCA2 and FANCD2). We also compared a
BRCA1-mutated, PARPi-sensitive triple negative breast cancer
(TNBC) cell line, MDA-MB436, to a BRCA-proﬁcient TNBC cell
line, HCC114353, and observed PARPi-induced γH2AX in MDA-
MB436 but not in HCC1143 cells, consistent with their PARPi-
sensitivity status (Fig. 2d).
Interestingly, recent work established that the cellular metabolite
and ubiquitous environmental toxin formaldehyde induces a
BRCA haploinsufﬁciency by accelerating degradation of BRCA2
and, to a lesser extent, BRCA1 and RAD51, which in turn
promotes genome instability54. Based on these ﬁndings, we tested
whether formaldehyde exposure would also cause PARPi hyper-
sensitivity in otherwise BRCA1/2 wild-type cells. Indeed, formal-
dehyde treatment resulted in a marked increase in PARPi-induced
S-phase-speciﬁc DNA damage signaling, consistent with compro-
mised BRCA function and suggesting that PARPi and formalde-
hyde functionally synergize (Supplementary Figure 3b).
We next tested whether we could monitor cellular responses to
a wider variety of genotoxic agents. First, we followed the induction
of DNA damage signaling upon ionizing radiation (IR) and
its gradual decay over time, unveiling a cell cycle independent
induction of γH2AX (Supplementary Figure 3c). We then moni-
tored single and combined treatments of chemotherapeutically
relevant genotoxic agents such as IR, the topoisomerase I poison
camptothecin (CPT), the methylating agent temozolomide (TMZ),
and the PARPi olaparib, to assess the potential therapeutic value of
different combination therapies. These experiments revealed
treatment-speciﬁc γH2AX patterns, which demonstrates their
differential effect on inducing the DDR, and provided a detailed
picture of how IR, CPT and TMZ synergize with PARPi, resulting in
a PARPi-induced S-phase speciﬁc increase of DNA damage
signaling (Supplementary Figure 3d). As before, focusing the
analysis only on S-phase cells increased the sensitivity of the readout
(Supplementary Figure 3d, lower panels). Thus, QIBC-based PARPi-
DDR measurements can reveal cytotoxic interactions with a variety
of chemotherapeutic agents and discern their relative strengths.
Cell cycle resolved quantiﬁcation of PARP trapping. PARPi-
induced cytotoxicity has been linked to an additional feature of
PARPi, namely their potential to lock PARP enzymes in an inactive
state and trap PARP enzymes and associated proteins on chromatin,
generating cytotoxic protein-DNA complexes25. Consistent with this
model, PARPi toxicity is relieved in the absence of PARP
enzymes22,23. PARP trapping has been detected biochemically by
chromatin fractionation experiments from bulk cell populations
exposed to the alkylating agent methyl methanesulfonate
(MMS)22,23. We aimed to test whether high-content single cell
imaging could provide an alternative means to evaluate and quantify
PARP trapping in a manner that would allow us to directly correlate
PARP trapping and PARPi-induced DNA damage signaling in the
same cells. By including a pre-extraction step prior to ﬁxation to
speciﬁcally detect chromatin-bound proteins46 we indeed observed a
marked increase in the chromatin retention of PARP1 when cells
were exposed to MMS and the PARPi olaparib for 4 h (Fig. 3a). In
the same cells, we measured γH2AX signaling (Fig. 3b) and EdU
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incorporation (Fig. 3c). Interestingly, while PARP1 trapping was
independent of the cell cycle, the initial DNA damage signaling after
1 h treatment occurred primarily in S-phase cells, supporting the
notion that PARP1 trapping occurs in all cell cycle phases but causes
most problems during DNA replication (Fig. 3d, e). The detected
signals for chromatin-bound PARP1 were speciﬁc (Supplementary
Figure 4a), and biochemical fractionation conﬁrmed the QIBC-
based PARP1 trapping results, although with lower sensitivity and
quantitative power, and without the possibility to directly correlate
PARP1 trapping to γH2AX formation at the single cell level (Sup-
plementary Figure 4b). We next tested three different PARPi (veli-
parib, olaparib, and talazoparib), which vary in their cytotoxicity and
PARP trapping potential29. While all three inhibitors resulted in
greatly enhanced chromatin retention of PARP1 in the presence of
MMS, veliparib had the weakest and talazoparib the strongest effect
(Fig. 4a). The degree of PARP1 trapping (talazoparib >> olaparib >>
veliparib) correlated with the degree of PARP inhibition as
revealed by measurements of hydrogen peroxide (H2O2) induced
poly(ADP-ribose) (PAR) formation (Fig. 4b) and with the amount
of S-phase-speciﬁc DNA damage signaling (Fig. 4c).
It was previously suggested that synergy between TMZ and PARPi
is based on PARP trapping in addition to PARP catalytic inhibition,
while synergy between CPT and PARPi is primarily due to PARP
catalytic inhibition and does not require PARP trapping23,25. In line,
we indeed observed elevated PARP1 chromatin retention upon
PARPi/TMZ but not PARPi/CPT (Supplementary Figure 4c, d),
consistent with the differential strength of synergism by these drug
combinations (Supplementary Figure 3d).
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Exposure to either MMS or the known PARP activator H2O2
led to elevated levels of detergent-resistant, chromatin-bound
PARP1 upon PARPi (Supplementary Figure 5a, b). However, we
were unable to detect signiﬁcant increases in PARP trapping
upon PARPi alone. While chromatin trapping of PARP1 and
associated proteins may occur in the presence of PARPi alone
below our detection limit, it is also possible that PARP trapping
occurs primarily under conditions when PARP enzymes are
highly activated and at the same time catalytically blocked.
Accordingly, genotoxins forming PARP-activating lesions might
generally work more via PARP trapping in conjunction with
PARPi as compared to drugs that do not result in high levels of
PARP activation. To consolidate this point and to test whether
the high-content imaging-based PARP1 trapping assay was
compatible with high-throughput screening, we performed a
proof-of-concept combinatorial drug screen in technical quad-
ruplicates at two different time-points in multiwell format and
simultaneously assessed chromatin-bound PARP1, γH2AX, and
EdU. This revealed both similarities and differences between the
different drug combinations at the level of PARP1 trapping, DNA
damage signaling and DNA replication (Supplementary Fig-
ure 5c). The technical replicates showed overall consistent results
(Supplementary Figure 5d, left panels), and the screen revealed
unexpected differences in the kinetics of PARP1 trapping and
γH2AX induction when comparing MMS and H2O2, although
both affected EdU incorporation in a very similar manner
(Supplementary Figure 5d, middle panels). It also provided
further insights into the synergy between TMZ and olaparib,
which we found to functionally interact at all measured
parameters (Supplementary Figure 5d, right panels). In all tested
conditions, PARP1 trapping occurred in a cell cycle-independent
manner. PARP trapping measurements by QIBC, combined with
additional markers of drug cytotoxicity, thus represent a
screening-compatible experimental pipeline to interrogate cellular
responses to single drugs and drug combinations.
Similar to PARP1 we could also observe PARP2 trapping
(Supplementary Figure 6a), in line with previous biochemical
data22. Analogous to PARP1, PARP2 trapping was cell cycle
independent, yet the associated DNA damage signaling in the same
cell population occurred primarily in S-phase cells (Supplementary
Figure 6b). To our knowledge this is the ﬁrst time that PARP1/2
trapping and DNA damage signaling can be directly correlated
in the same cell population in a cell cycle resolved manner, and
the results provide experimental support for previous models
on PARPi-induced PARP trapping (across the cell cycle) and
replication-associated formation of DNA lesions (in S-phase).
Loss of PARP enzymes confers resistance to PARPi. Acquired
drug resistance in advanced disease is a major challenge for PARPi
treatments and other targeted cancer therapies5. Mutation or
down-regulation of PARP enzymes is one of the few mechanisms
known to alleviate PARPi sensitivity and can lead to PARPi
resistance22,28,55,56. PARP1 downregulation using siRNA indeed
resulted in reduced S-phase-speciﬁc γH2AX signaling, providing
further evidence that our read-outs reﬂect a cytotoxic consequence
of PARPi-mediated PARP1 dysfunction (Supplementary
Figure 7a). The rescue of DNA damage signaling was clearly
detectable yet incomplete, which could be due to a contribution by
other PARP family members. We therefore performed a series of
PARP knockdowns and assessed DNA damage signaling upon
exposure to three different PARPi (veliparib, olaparib, and tala-
zoparib). Interestingly, while both PARP1 and PARP2 (but not
PARP3) seemed to contribute to veliparib- and olaparib-induced
γH2AX formation, talazoparib-induced DNA damage was mark-
edly reduced only by PARP1 depletion (Supplementary Figure 7b,
c). Thus, the relative contribution of different PARP family
members can be assessed for different PARPi in short-term phe-
notypic assays, which can complement fractionation-based trap-
ping experiments in bulk populations22,57.
Since poly(ADP-ribosyl)ation (PARylation) is controlled by both
PARP activity and PAR degradation, we next asked whether
deregulated PAR turnover would also impact PARPi-DDR.
Interestingly, depletion of PARG, the main antagonizer of nuclear
PARylation, resulted in reduced levels of S-phase-speciﬁc DNA
damage signaling upon PARPi exposure, indicating that PARG-
mediated turnover of PAR may contribute to PARPi toxicity
(Supplementary Figure 8a). While we did not observe extenuated
PARP1 or PARP2 trapping upon PARG knockdown (Supplemen-
tary Figure 8b, c), depletion of PARG did rescue PAR levels in
PARPi-treated cells (Supplementary Figure 8d), suggesting that the
knockdown was functional and that loss of PARG can impact the
efﬁciency with which PARPi block cellular PARylation. Moreover,
we observed that the PARPi-induced formation of RAD51 and
BRCA1 foci was eased in PARG-depleted cells, indicative of
partially restored PARP functions under these conditions (Supple-
mentary Figure 9a, b). While elucidating the exact mechanism of
relieved PARPi toxicity upon PARG loss needs further work, these
results suggest that PARG expression and its activity may be
relevant parameters of PARPi toxicity and resistance.
Multidimensional analysis of PARPi-induced cell cycle arrest.
As additional parameters of cytotoxicity we assessed the con-
sequences of PARPi-DDR on cell cycle progression. Short-term
experiments conﬁrmed that PARPi-induced DNA damage sig-
naling is detectable within 30 min of inhibitor exposure (Fig. 5a)
and found that the highly potent PARPi talazoparib induces
higher amounts of S-phase damage compared to olaparib
(Fig. 5a). When cells were incubated for 24 h with increasing
inhibitor concentrations and stained for Cyclin A to allow for
two-dimensional cell cycle staging, we observed a pronounced
and dose-dependent accumulation of cells in S/G2 and, consistent
with the degree of DNA damage induction, the S/G2 accumula-
tion was stronger in talazoparib as compared to olaparib treated
cells (Fig. 5b, c). For a more detailed analysis we performed
4-dimensional (4D) cell cycle staging based on DAPI, Cyclin A,
EdU and the mitotic marker H3pS10 (Serine10-phosphorylated
histone H3) (Supplementary Figure 10a–c). Whereas olaparib-
treated cells slowed down DNA replication and accumulated in S/
G2, talazoparib-treated cells had even more severe problems
during S-phase progression and accumulated mostly there
(Supplementary Figure 10a, b). Both compounds resulted in loss
of mitotic cells marked by H3pS10, and, consistent with the
effects on S-phase progression, this was more pronounced for
talazoparib as compared to olaparib (Supplementary Figure 10c).
Thus, PARPi-DDR measurements can be ﬂexibly adjusted to
monitor and evaluate consequences of PARPi at multiple cellular
levels.
Exploring drug interactions by quantitative imaging. PARPi
synergize with checkpoint kinase inhibitors such as inhibitors of
the DNA damage response kinase ATR (ATRi)58,59, however the
underlying mechanisms are incompletely understood. To inves-
tigate this synthetic lethal interaction in more detail, we plotted
total versus mean DAPI intensities of olaparib-, ATRi- and ola-
parib/ATRi-treated U-2 OS cells and assessed γH2AX formation.
γH2AX signaling occurred primarily in cells with high mean
DAPI intensities, i.e., cells with condensed chromatin (Fig. 6a).
Co-staining with H3pS10 validated that cells with high mean
DAPI intensities were mitotic cells and showed that ATRi treat-
ment increased the percentage of PARPi-exposed cells
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progressing into mitosis, where they experience high levels of
DNA damage (Fig. 6b and Supplementary Figure 11a–d). To
further exploit the predictive power of cell cycle resolved feature
extraction from asynchronous cell populations we measured
chromosome condensation and chromosome area in mitotic
cells. This revealed that upon combined PARPi/ATRi treatment
mitotic chromosomes were overall more condensed (Fig. 6c) and
occupied a smaller area (Fig. 6d). Metaphase spreads were in line
with this observation and showed signiﬁcant chromosome shat-
tering in the combined treatment (Fig. 6e). To consolidate this
result, we performed live cell imaging experiments for up to 48 h
covering two rounds of cell division in control cells using H2B-
GFP U-2 OS cells (Supplementary Figure 12a). ATRi-treated cells
showed an extended mitotic duration, which was associated with
lagging chromosomes, anaphase bridges and micronuclei for-
mation upon completion of mitosis (Supplementary Figure 12b).
PARPi treatment resulted in a G2 arrest (Supplementary Fig-
ure 12c), consistent with our previous results (Fig. 5 and Sup-
plementary Figure 10). Combined PARPi/ATRi treatment,
however, resulted in severely extended mitotic duration, even-
tually leading to catastrophic damage and genome disintegration
(Supplementary Figure 12d). Consistently, CDK inhibition to
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block mitotic entry abolished chromosome breakage and
γH2AX formation in PARPi/ATRi-treated cells (Supplementary
Figure 13a).
Replication intermediates occurring upon replication stress
frequently escape cell cycle checkpoints and can be transmitted to
the next cell cycle, where they are marked by the genome
caretaker protein 53BP160. We found 53BP1 nuclear bodies to
increase drastically upon combined PARPi/ATRi treatment,
suggesting that those cells, which can exit mitosis, do so with
elevated inherited DNA damage (Supplementary Figure 11e).
Besides its function in controlling the G2/M transition, ATR
promotes RAD51 recruitment to stalled or collapsed replication
forks and fosters DNA repair by homologous recombination61.
Consistently, ATRi suppressed olaparib-induced RAD51 foci
formation in S-phase cells (Supplementary Figure 13b), indicating
that ATRi and PARPi synergize during S-phase progression, and
that S-phase-born DNA lesions are then transmitted to mitosis,
where, depending on the severity of the damage, they can either
cause catastrophic chromosomal shattering or give rise to greatly
elevated inherited DNA damage in the following G1 phase.
Last, to evaluate whether the approach could help uncover novel
mechanisms of drug synergism beyond PARPi/ATRi, we performed
a targeted siRNA-based pilot screen focusing on a small set of
custom-selected cell cycle checkpoint and ATR/CHK1-related
genes. We transfected cells in a 96-well format, left one set
untreated and treated a second set for 8 h with olaparib, and
measured DAPI, EdU and γH2AX intensities (Fig. 7a). Using three
independent siRNAs per gene we analyzed around 2 million
parameters of more than 200,000 cells. When we ranked genes
according to γH2AX levels in EdU-positive S-phase cells we found
siPARP1 to have the most negative z-score (Fig. 7b), consistent with
our previous results on alleviated PARPi toxicity upon loss of
PARP1. On the other extreme, we identiﬁed the replication
checkpoint mediators RAD9A and NEK861,62, as well as TIME-
LESS, which, in addition to promoting replication fork stability, was
recently shown to interact with PARP1 and foster DSB repair63,64.
We also identiﬁed SKP1 and CUL1, two components of the SKP,
Cullin, F-box containing complex (SCF complex), as regulators of
PARPi toxicity. This caught our attention, as SCF inhibition is
currently assessed in phase I/II clinical trials to treat malignancies65.
Re-investigation of our screening data conﬁrmed that all three
CUL1 and SKP1 siRNAs sensitized to olaparib (Fig. 7c and data not
shown). SCF targeting in clinical tests is achieved by the NEDD8
inhibitor pevonedistat (MLN4924)66, and we therefore wondered
whether pevonedistat would synergize with PARPi. Long-term
clonogenic survival assays showed that a combination of pevonedi-
stat and olaparib was signiﬁcantly more cytotoxic than single drug
treatments (Fig. 7d). While PARP1 levels were not altered upon
pevonedistat treatment (Supplementary Figure 14a–c), we observed
elevated PARP1 trapping when pevonedistat was combined with
olaparib (Fig. 7e). Normal formation of PARPi-induced RAD51
and BRCA1 foci suggested that pevonedistat-treated cells are not
compromised in BRCA1/2 functions (Supplementary Figure 14d,
e). The elevated PARP1 trapping, however, prompted us to test
whether the synergism between pevonedistat and olaparib required
PARP1 itself. Remarkably, down-regulation of PARP1 alleviated
both the DNA damage signaling and the cell cycle arrest induced by
the pevonedistat/olaparib combination (Fig. 7f). Thus, NEDD8/SCF
inhibition by pevonedistat causes a hitherto uncharacterized
cytotoxic interaction with PARPi, which depends on the presence
of PARP1. Although the exact mechanism of interaction awaits
further studies, our data suggest that it works at least partially via
PARP1 trapping, raising the possibility that cancer cells with high
expression of PARP1, even in a BRCA1/BRCA2-proﬁcient scenario,
may be particularly vulnerable to combined pevonedistat/PARPi
treatments.
Discussion
PARPi represent the ﬁrst class of targeted therapeutics, which
have been approved for cancer treatment based on the concept of
synthetic lethality. While the molecular targets of PARPi are
known and their biochemical activities have been characterized
extensively, the cellular responses to PARPi have remained largely
elusive. Deﬁning the road from inhibiting PARP enzymatic
activity to PARPi-induced cell death will be crucial to tackle the
“holy trinity” in personalized cancer therapy28: deciding whom to
treat based on biomarker-guided patient stratiﬁcation, combating
drug resistance by identifying mechanisms and predictive mar-
kers of reduced PARPi sensitivity, and optimizing combination
therapy. Here we report an easy-to-implement and cost-efﬁcient
experimental pipeline that monitors, at the single-cell level and
with sub-cellular resolution, the dynamics of the cellular response
to PARPi in a sensitive and reliable manner, and can thereby aid
all three areas of PARPi-based cancer therapy (Fig. 8).
Employing multidimensional high-content microscopy we
present insights into cytotoxic interactions between PARPi and
other clinically relevant agents (e.g., ATRi, topoisomerase block-
ers, and environmental toxins such as formaldehyde), and
provide detailed views on the cellular responses to PARPi, their
progression over time, and how deregulation of PARP enzymes
impacts PARPi-induced DNA damage signaling. By simulta-
neously assessing PARPi-induced PARP trapping and γH2AX
induction, we show that although PARP trapping occurs in all
phases of the cell cycle, the DNA damage signal primarily occurs
in S-phase cells. These results support the notion that cytotoxic
PARPi-provoked DNA lesions arise in the context of DNA
replication. The type(s) of lesions underlying PARPi toxicity
potentially comprise multiple deleterious structures, including
DNA-protein complexes, which form upon PARP enzymes being
locked in an inactive conformation and which may pose an
obstacle for the replication machinery, replication-associated
conversion of DNA single- into double-strand breaks, reversed
and degraded replication forks, as well as hitherto uncharacterized
cytotoxic PARPi-induced structures. While complementary
experimental approaches are needed to investigate the exact nat-
ure of these structures, QIBC-guided analyses are powerful tools
for phenotypic explorations of drug interactions. Our data suggest
that pevonedistat, a novel pharmacologic inhibitor of the NEDD8/
SCF system currently being tested in phase I/II clinical trials66,
sensitizes cells to PARPi. Importantly, our ﬁndings further suggest
that the synergism between PARPi and pevonedistat may rely on
elevated levels of DNA lesions rather than compromised HR
function. Interestingly, we show a PARP1 dependency and
increased PARP1 trapping upon combined PARPi/pevonedistat
treatment, suggesting that the NEDD8/SCF machinery may play a
role in regulating PARP1 function and chromatin retention. These
ﬁndings provide a rationale for future studies to mechanistically
dissect the interplay between the SCF complex and PARP1 in the
context of PARPi and to assess its clinical potential.
We envision that PARPi-DDR measurements as presented
here can complement existing cell population-based proteomics
and genomics approaches to interrogate physiological PARP
functions67–69, and that it will prove valuable in basic and pre-
clinical research to predict, identify and characterize mechanisms
of PARPi sensitivity and resistance and explore in targeted assays
and large scale combinatorial screens new drug combinations for
synergistic effects. Provided that suitable markers can be gener-
ated and smartly combined in cells to assess PARPi effects live
(e.g., antibody-independent surrogate markers for DNA damage
signaling, HR function, cell cycle progression, etc.) high-content
time-lapse imaging may provide even more detailed views on
drug cytotoxicity in the future. Given the general adaptability of
image-based single-cell assays to pre-clinical and clinical research
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settings such developments may eventually help predict clinical
outcomes and stratify cancer patients.
Methods
Cell culture and drug treatments. All cells were grown in a sterile cell culture
environment and routinely tested for mycoplasma contamination. Human U-2 OS
cells (authenticated by STR proﬁling), U-2 OS derived H2B-GFP cells and hTERT-
RPE1 cells (ATCC), were grown under standard cell culture conditions (humidiﬁed
atmosphere, 5% CO2) in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
10% fetal bovine serum (GIBCO) and penicillin-streptomycin antibiotics. MDA-MB-
436 cells were provided by Mohamed Bentires-Alj, University of Basel, and were
grown in DMEM containing 10% fetal bovine serum and penicillin-streptomycin
antibiotics. HCC1143 cells were also provided by Mohamed Bentires-Alj, University
of Basel, and were grown in RPMI-1640 medium containing 10% fetal bovine serum
and penicillin-streptomycin antibiotics. For pulsed EdU (5-ethynyl-2′-desoxyuridine)
(Thermo Fisher Scientiﬁc) incorporation, cells were incubated for 20min in medium
containing 10 μM EdU. The Click-iT EdU Alexa Fluor Imaging Kit (Thermo Fisher
Scientiﬁc) was used for EdU detection. Unless stated otherwise the following com-
pounds were used in this manuscript at the indicated ﬁnal concentrations: Az-20
(1 μM) (Tocris), Camptothecin (50 nM to 1 μM) (Selleckchem), Temozolamide
(1 mM) (T2577, Sigma), Roscovitine (20 μM) (Selleckchem), PJ-34 (10 μM) (ALX-
270–289-M001, Enzo Life Sciences), niraparib (MK-4827) (10 μM) (S2741, Sell-
eckchem), rucaparib (AG-014699, PF-01367338) (10 μM) (S1098, Selleckchem),
talazoparib (BMN 673) (50 nM-10 μM) (S7048, Selleckchem), veliparib (ABT-888)
(10 μM) (ALX-270–444-M005, Enzo Life Sciences), olaparib (AZD-2281) (50nM-10
μM) (S1060, Selleckchem), pevonedistat (MLN4924) (10 nM to 100 nM) (S7109,
Selleckchem), Hydrogen peroxide (H3410, Sigma-Aldrich) (0.1mM), Methyl
methanesulfonate (129925, Sigma-Aldrich) (0.01%). X-ray irradiation of cells was
performed with a Faxitron Cabinet X-ray System Model RX-650. For cell synchro-
nization and release experiments, exponentially growing U-2 OS cells were incubated
with 2mM thymidine for 20 h and subsequently washed and cultured in fresh
medium with or without olaparib (10 μM) for 6 h.
siRNA transfections. Duplex siRNA transfections were performed for 72 h with
Ambion Silencer Select siRNAs using Lipofectamine RNAiMAX (Thermo Fisher
Scientiﬁc). The following Silencer Select siRNAs were used at a ﬁnal concentration
of 25 nM: PARP1 (s1098), PARP2 (s19504), PARP3 (s19507), FANCD2 (s4988),
BRCA1 (s459), BRCA2 (s2085). PARG knockdown (s16158) was performed for 36
h at a ﬁnal concentration of 5 nM. When several siRNAs were combined, the ﬁnal
siRNA concentration was kept constant at 25 nM for all conditions. Negative
control (s813) from Ambion was used as a non-targeting control and is abbreviated
siCon. The siRNA-based screen was performed by reverse-transfection of U-2 OS
cells cultured in CELLSTAR 96-well-plates (Greiner Bio-One) for 48 h at a cell
density of 6000 cells per well at the time of transfection with Ambion Silencer
Select siRNAs at a ﬁnal concentration of 5 nM using HiPerFect (Qiagen) reagent.
Histone extraction. For acid extraction of histones, cell pellets were resuspended
in Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X 100 (v/v), 2 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 0.02% (w/v) NaN3) at a cell density of
107 cells per ml and lysed on ice for 10 min. Cells were centrifuged at 6500×g for
10 min at 4 °C and then washed with TEB at a cell density of 2 × 107 cells per ml.
Cell pellets were resuspended in 0.2 N HCl at a density of 4 × 107 nuclei per ml and
extracted over night at 4 °C. Samples were centrifuged at 6500×g for 10 min at 4 °C
and the supernatants neutralized with 20% 1M NaOH. Protein amounts were
quantiﬁed using the standard Bradford method.
Immunochemical methods. Proteins were resolved by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto polyvinylidene ﬂuoride (PVDF)
membranes. Membranes were blocked with PBS-Tween20 (0.01%) containing 5%
milk powder for 1 h at room temperature. Primary antibodies in blocking solution
were applied over night at 4 °C. The following primary antibodies were used for
western blot analysis: Histone H3 (rabbit, Abcam ab1791, 1:20,000), H2AX
Phospho S139 (mouse, Biolegend 613401, 1:500), PARP1 (rabbit, Santa Cruz sc-
7150, 1:500), NFκB p65 (rabbit, Santa Cruz sc-109, 1:500), p27 (rabbit, Santa Cruz
sc-528, 1:500), PCNA (mouse, Santa Cruz sc-56, 1:500). Secondary horseradish
peroxidase-coupled antibodies (Vector labs VC-PI-1000-M001 and VC-PI-2000-
M001, 1:10,000) were applied for 1 h at room temperature in PBS-Tween20
(0.01%) containing 1% milk powder prior to detection by ECL-based chemilumi-
nescence. Western blot scans used to assembly the ﬁgures are provided in Sup-
plementary Figure 15a–d.
Immunostaining. Cells were seeded onto sterile 12 mm glass coverslips inside
60 mm cell culture dishes, or into multiwell plates (CELLSTAR 96-well-plates,
Greiner Bio-One), and grown for 24 h to reach a cell density of 70–90%. After
applying the indicated cell treatments, cells were ﬁxed in 3% formaldehyde in PBS
for 15 min at room temperature, washed once in PBS, permeabilized for 5 min at
room temperature in 0.2% Triton X-100 (Sigma-Aldrich) in PBS, washed twice in
PBS and incubated in blocking solution (ﬁltered DMEM containing 10% FBS and
0.02% Sodium Azide) for 15 min at room temperature. Where indicated, cells were
pre-extracted in 0.2% Triton X-100 in PBS for 2 min on ice prior to formaldehyde
ﬁxation. All primary antibodies (see below for speciﬁcations) and secondary
antibodies (Alexa Fluor 488 goat-anti rabbit, Alexa Fluor 488 goat-anti mouse,
Alexa Fluor 568 goat-anti rabbit, Alexa Fluor 568 goat-anti mouse, Alexa Fluor 647
goat-anti rabbit, Alexa Fluor 647 goat-anti mouse, all Thermo Fisher Scientiﬁc,
1:500) were diluted in blocking solution. For antibody incubations the coverslips
were inverted over 40 μl of the desired antibody for 1–2 h at room temperature. For
immunostaining in multiwell plates, 40 μl of the desired antibody was used per
well. When combining the staining with an EdU Click-it reaction, this reaction was
performed prior to incubation with the primary antibodies according to the
manufacturer’s recommendations (Thermo Fisher Scientiﬁc). Following antibody
incubations, coverslips were washed once with PBS and incubated for 10 min with
PBS containing 4',6-Diamidino-2-Phenylindole Dihydrochloride (DAPI, 0.5 μg/ml)
at room temperature to stain DNA. Following three washing steps in PBS, cov-
erslips were brieﬂy washed with distilled water and mounted on 5 μl Mowiol-based
mounting media (Mowiol 4.88 (Calbiochem) in Glycerol/TRIS). Multiwell plates
were subjected to the same DAPI staining and washing procedure and were then
PARPi
γH2AX RAD51
Replication
PARylation
PARP trapping
Cell cycle arrestMitotic damage
PARP PARP
Fig. 8 Multidimensional analysis of PARPi toxicity by cell cycle resolved automated high-content microscopy. Key parameters of the cellular response to
PARPi are simultaneously quantiﬁed, including DNA damage signaling (measured by γH2AX formation), activation of the homologous recombination
repair pathway (measured by RAD51 foci formation), slow-down of DNA replication (measured by EdU incorporation), inhibition of PARP enzymes
(measured by changes in poly(ADP-ribose) (PAR) levels), trapping of PARPs (measured by PARP levels after in situ fractionation), cell cycle arrest
(measured by accumulation of cells in speciﬁc cell cycle phases), and mitotic chromosomal damage (measured by γH2AX on mitotic chromosomes). The
experimental pipeline is equally suited for individual assays and large scale high-throughput screens
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kept in PBS. The following primary antibodies were used for immunostaining:
H2AX Phospho S139 (mouse, Biolegend 613401, 1:1000), RAD51 (rabbit, Bioa-
cademia 70-002, 1:1000), BRCA1 (mouse, Santa Cruz sc-6954, 1:100), Poly(ADP-
ribose) (rabbit, Enzo Lifesciences ALX-210–890, 1:1000), Cyclin A (rabbit, Santa
Cruz sc-751, 1:100), PARP1 (rabbit, Santa Cruz sc-7150, 1:100), PARP2 (rabbit,
Active Motif 39743, 1:250), Histone H3 phospho S10 (rabbit, Abcam ab5176,
1:2000), 53BP1 (rabbit, Santa Cruz sc-22760, 1:500).
Quantitative image-based cytometry. Automated multichannel wide-ﬁeld
microscopy for quantitative image-based cytometry (QIBC)43–46 was performed on
an Olympus ScanR Screening System equipped with an inverted motorized Olympus
IX83 microscope, a motorized stage, IR-laser hardware autofocus, a fast emission ﬁlter
wheel with single band emission ﬁlters, and a 12 bit digital monochrome Hamamatsu
ORCA-FLASH 4.0 V2 sCMOS camera (2048 × 2048 pixel, 12 bit dynamics). For each
condition, image information of large cohorts of cells (typically at least 500 cells for
the UPLSAPO 40× objective (NA 0.9), at least 2000 cells for the UPLSAPO 20×
objective (NA 0.75), and at least 5000 cells for the UPLSAPO 10× (NA 0.4) and
UPLSAPO 4× (NA 0.16) objectives) was acquired under non-saturating conditions at
a single autofocus-directed z-position. Identical settings were applied to all samples
within one experiment. Images were analyzed with the inbuilt Olympus ScanR Image
Analysis Software Version 2.5.1, a dynamic background correction was applied, nuclei
segmentation was performed using an integrated intensity-based object detection
module using the DAPI signal, and foci segmentation was performed using an
integrated spot-detection module. All downstream analyses were focused on properly
detected interphase nuclei or mitotic chromosomes containing a 2C-4C DNA content
as measured by total and mean DAPI intensities. Fluorescence intensities were
quantiﬁed and are depicted as arbitrary units. Color-coded scatter plots of asyn-
chronous cell populations were generated with Spotﬁre data visualization software
(TIBCO). Within one experiment, similar cell numbers were compared for the dif-
ferent conditions. For visualizing discrete data in scatter plots (e.g., foci numbers),
mild jittering (random displacement of data points along the discrete data axes) was
applied in order to demerge overlapping data points. Representative scatter plots and
quantiﬁcations of independent experiments, typically containing several thousand
cells each, are shown.
Metaphase spreads. U-2 OS cells were treated with olaparib (10 μM) and
AZ-20 (1 μM) for 24 h, arrested with Colcemid (Roche) at a ﬁnal concentration of
100 ng/ml during the last 12 h of the treatments, harvested by trypsinization,
swollen in 75 mM KCl for 30 min at 37 °C and ﬁxed in methanol:acetic acid 3:1.
Aliquots of the cellular suspension were dropped onto microscopy slides to obtain
chromosome spreads, which were stained with DAPI (0.5 μg/ml) and mounted
with Mowiol-based mounting media. Image acquisition was performed on a Leica
SP8 laser-scanning microscope equipped with solid-state diode lasers for 405 nm
(50 mW), 488 nm (20 mW), 552 nm (20 mW), and 638 nm (30 mW) using an HCX
PL APO CS2 63× immersion oil objective (NA 1.4).
Time-lapse microscopy. Time-lapse microscopy of H2B-GFP U-2 OS cells was
performed on the Olympus ScanR Screening System under CO2 (5%) and tem-
perature (37 °C) control and employing an inbuilt infrared-based hardware auto-
focus. Exposure times were kept minimal to avoid phototoxicity. Cells were plated
on multiwell plates (CELLSTAR 96-well-plates, Greiner Bio-One) at a density of
8000 cells per well 24 h prior to imaging. Images were taken at 15 min intervals for
48 or 72 h as indicated in the ﬁgure legends using a UPLSAPO 20× objective
(NA 0.75). During the time-lapse imaging cells were cultured with FluoroBrite
DMEM medium containing 10% FCS (GIBCO) and penicillin-streptomycin.
Flow cytometry. Cells were ﬁxed with chilled 70% ethanol, permeabilized with
0.05% Tween-20 in PBS, incubated for 2 h at room temperature with an antibody
recognizing H2AX Phospho S139 (mouse, Biolegend 613401, 1:500), followed by
incubation with the secondary antibody against mouse immunoglobulin labeled
with a green ﬂuorophore (Alexa Fluor 488 Life Technologies, 1:500) during 1 h at
room temperature. Finally, DNA was stained with propidium iodide (PI) (50 µg/
ml). Samples were acquired and analyzed in a Fortessa LSRII ﬂow cytometer
(Beckton Dickinson). The generated data were processed using the Spotﬁre data
visualization software (TIBCO).
RNA extraction and quantitative PCR. RNA was puriﬁed with TRIzol reagent
(Life Technologies). RNA was primed with random hexamers (11034731001,
Roche) and reverse-transcribed to cDNA using a MultiScribe Reverse Transcriptase
(4311235, Thermo Fisher). qPCR was performed with the KAPA SYBR FAST
qPCR Kit (KAPA Biosystems) on a Rotor Gene Q system (Qiagen). Relative
transcription levels were obtained by normalization to Eif2c2 expression.
The following primer pairs were used:
hPARP1 F:GCATCAGCACCAAAAAGGAGGTGG
hPARP1 R:GATTTGTTGATACCTTCCTCCTTGACCTGG
hPARP2 F:GTGGAGAAGGATGGTGAGAAAG
hPARP2 R: CTCAAGATTCCCACCCAGTTAC
hPARP3 F:GCAAGTCAGCTGGATATGTTATTG
hPARP3 R:CGTGTTGATATGGTGCTCTCT
hPARG F: CGAGCAGGAGAAGTTCCTAAAC
hPARG R: AGTTCGCTCACCATTCTCATC
hBRCA1 F: TGAAATCAGTTTGGATTCTGC
hBRCA1 R: CATGCAAGTTTGAAACAGAAC
hBRCA2 F: CCAAAGTTTGTGAAGGGTCG
hBRCA2 R: GTAGAACTAAGGGTGGGTGGTG
hFANCD2 F: AAAACGGGAGAGAGTCAGAATCA
hFANCD2 R: ACGCTCACAAGACAAAAGGCA
hEIF2C2 F:GTCCCTTTTGAGACGATCCAG
hEIF2C2 R:AGCCAAACCACACTTCTCG
Chromatin fractionation. Cell pellets were collected by scraping in 1× PBS with 1×
protease inhibitor (cOmplete, Roche) and split in two equal fractions: (A) For the
total proteome cells were resuspended in 1× MNase buffer (0.3 M Sucrose, 50 mM
Tris pH 7.5, 30mM KCl, 7.5 mM NaCl, 4 mM MgCl2, 1 mM CaCl2, 0.125% NP-40,
0.25% Na-Deoxycholate) with 1× protease inhibitor and 10 U of MNase
(10107921001, Roche) for every 5 million cells. Cells were incubated for 30min at
37 °C, boiled in 1× SDS-loading buffer for 5 min, spun down at 16,000×g for 5 min
and the supernatant was collected for western blot. (B) For chromatin-bound and
soluble fractions cells were resuspended in chromatin extraction buffer (10mM
Hepes pH 7.6, 3 mM MgCl2, 0.5% Triton-X-100, 1 mM DTT) with 1× protease
inhibitor. Cells were rotated for 30min at room temperature and spun down at
1300×g for 10 min at 4 °C. The supernatant was collected, spun down at 16,000×g
for 5 min at 4 °C and the supernatant was collected again (soluble fraction), boiled
in 1× SDS-loading buffer for 5 min, spun down at 16,000×g for 5 min and the
supernatant was collected for western blot. The pellet of the chromatin extraction
step (chromatin-bound fraction) was resuspended in MNase buffer with 1× protease
inhibitor and 10U of MNase for every 5 million cells. Cells were incubated for
30 min at 37 °C, boiled in 1× SDS-loading buffer for 5 min, spun down at
16,000×g for 5 min and the supernatant was collected for western blot. Protein
amounts were quantiﬁed using the standard Bradford method before addition of
SDS-loading buffer.
Clonogenic survival assay. U-2 OS cells were seeded at single cell density and 24
h later incubated with olaparib (1 μM), pevonedistat (10 nM) or a combination of
both. Cells were incubated for 10 days and the number of colonies with more than
50 cells was counted after staining with crystal violet (0.5% crystal violet in 20%
ethanol).
Statistical analysis. Mann–Whitney test was used for statistical analysis of
microscopy-derived intensity data. Unpaired t-test was used for clonogenic survival
data.
Data availability. All relevant data are available from the authors.
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